AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10500946 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group C)
Number of subjects: 180
Study 1907447 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon dioxide laser
Number of subjects: 0
Study 1907447 — intervention group
Group type: COMPARATOR
Intervention: Scalpel
Number of subjects: 0
Study 1907447 — intervention group
Group type: COMPARATOR
Intervention: Electrosurgery
Number of subjects: 0
Study 6859607 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental 3 mg/kg, iv, followed by inhalation of 100% oxygen and a continuous intravenous infusion of thiopental 0.2‐0.3 mg X kg‐1 X min‐1
Number of subjects: 24
Study 6859607 — intervention group
Group type: COMPARATOR
Intervention: Thiopental 3 mg/kg followed by inhalation of halothane (1.5% end‐tidal concentration) in oxygen
Number of subjects: 24
Study 6859607 — intervention group
Group type: COMPARATOR
Intervention: Thiopental 3 mg/kg followed by inhalation of 70% nitrous oxide in oxygen
Number of subjects: 24
Study 31911613 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control
Number of subjects: 9237
Study 31911613 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure control
Number of subjects: 9237
Study 31409425 — intervention group
Group type: EXPERIMENTAL
Intervention: Stop-X intervention (home-based motor-control training)
Number of subjects: 0
Study 31409425 — intervention group
Group type: COMPARATOR
Intervention: Postoperative guideline rehabilitation plus Classic follow-up treatment
Number of subjects: 0
Study 26944808 — intervention group
Group type: EXPERIMENTAL
Intervention: Get Active
Number of subjects: 38
Study 26944808 — intervention group
Group type: EXPERIMENTAL
Intervention: Sit Less
Number of subjects: 38
Study 26944808 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 38
Study 26725296 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported-employment services (randomization)
Number of subjects: 194
Study 27142743 — intervention group
Group type: EXPERIMENTAL
Intervention: Theaflavins (TF) 10mg/kg single oral dose
Number of subjects: 0
Study 27142743 — intervention group
Group type: EXPERIMENTAL
Intervention: Theaflavins (TF) 10mg/kg/day for 2 weeks
Number of subjects: 0
Study 27142743 — intervention group
Group type: COMPARATOR
Intervention: Theaflavin drink (45mg/drink)
Number of subjects: 0
Study 23828232 — intervention group
Group type: EXPERIMENTAL
Intervention: Violent offenders
Number of subjects: 29
Study 22315746 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) nasal spray 110 microg/day
Number of subjects: 220
Study 22315746 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) nasal spray 200 microg/day
Number of subjects: 220
Study 17928806 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg elemental calcium daily for 30 days (n=24)
Number of subjects: 44
Study 17928806 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=20)
Number of subjects: 44
Study 17928806 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium group
Number of subjects: 44
Study 17928806 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 44
Study 16905024 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide spraying intervention
Number of subjects: 302
Study 16905024 — intervention group
Group type: COMPARATOR
Intervention: Mass antibiotic treatment (azithromycin)
Number of subjects: 302
Study 15547521 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal prolapse and incontinence surgery
Number of subjects: 176
Study 15547521 — intervention group
Group type: EXPERIMENTAL
Intervention: Age <60 years
Number of subjects: 176
Study 15547521 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative pelvic organ prolapse quantification stage III or IV
Number of subjects: 176
Study 11251138 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-gauge Tuohy needle with loss-of-resistance (LOR) technique
Number of subjects: 100
Study 11251138 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopy confirmation
Number of subjects: 100
Study 10233493 — intervention group
Group type: EXPERIMENTAL
Intervention: VIP/P-1 (25 micrograms VIP combined with 1.0 mg PM)
Number of subjects: 236
Study 10233493 — intervention group
Group type: EXPERIMENTAL
Intervention: VIP/P-2 (25 micrograms VIP combined with 2.0 mg PM)
Number of subjects: 236
Study 10233493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 236
Study 7697277 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat and moisture exchanger (Group 1)
Number of subjects: 131
Study 7697277 — intervention group
Group type: COMPARATOR
Intervention: Heated humidifier (Group 2)
Number of subjects: 131
Study 2774267 — intervention group
Group type: EXPERIMENTAL
Intervention: Ohio anesthesia ventilator, N2O/O2
Number of subjects: 54
Study 2774267 — intervention group
Group type: EXPERIMENTAL
Intervention: Ohio anesthesia ventilator, N2/O2
Number of subjects: 54
Study 2774267 — intervention group
Group type: COMPARATOR
Intervention: Siemens ventilator (groups 1 and 2)
Number of subjects: 54
Study 353721 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomifensine, 4 capsules daily for 4 weeks
Number of subjects: 65
Study 353721 — intervention group
Group type: COMPARATOR
Intervention: Nortriptyline, 4 capsules daily for 4 weeks
Number of subjects: 65
Study 31718332 — intervention group
Group type: EXPERIMENTAL
Intervention: Epi-no® device, inflated within the vagina to measure maximum circumference
Number of subjects: 32
Study 31278694 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine ARER 100 mg under fed conditions
Number of subjects: 28
Study 31278694 — intervention group
Group type: COMPARATOR
Intervention: Morphine ARER 100 mg under fasted conditions
Number of subjects: 28
Study 28557548 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride extended-release chewable tablets (MPH ERCT) at 20-60 mg/day
Number of subjects: 90
Study 28557548 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride extended-release chewable tablets (MPH ERCT)
Number of subjects: 90
Study 28557548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 26559364 — intervention group
Group type: EXPERIMENTAL
Intervention: Wet-cupping (hijama) in addition to conventional hypertension treatment
Number of subjects: 80
Study 26559364 — intervention group
Group type: COMPARATOR
Intervention: Conventional hypertension treatment only
Number of subjects: 80
Study 23583166 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic retinopathy screening with a small copayment
Number of subjects: 2766
Study 23583166 — intervention group
Group type: COMPARATOR
Intervention: Free access to diabetic retinopathy screening
Number of subjects: 2766
Study 22413378 — intervention group
Group type: EXPERIMENTAL
Intervention: Federally funded family finding project
Number of subjects: 0
Study 22413378 — intervention group
Group type: COMPARATOR
Intervention: Standard child welfare services
Number of subjects: 0
Study 20139574 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium phosphate cement (CPC)
Number of subjects: 60
Study 20139574 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite ceramic granules (HAG)
Number of subjects: 60
Study 20139574 — intervention group
Group type: COMPARATOR
Intervention: Control (debridement alone)
Number of subjects: 60
Study 16927385 — intervention group
Group type: EXPERIMENTAL
Intervention: Short and long term family therapy
Number of subjects: 0
Study 15567633 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand delivery of questionnaires
Number of subjects: 802
Study 15567633 — intervention group
Group type: EXPERIMENTAL
Intervention: Long questionnaire (14 pages)
Number of subjects: 802
Study 15567633 — intervention group
Group type: EXPERIMENTAL
Intervention: Short questionnaire (8 pages)
Number of subjects: 802
Study 15567633 — intervention group
Group type: COMPARATOR
Intervention: Post delivery of questionnaires
Number of subjects: 802
Study 11395233 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy for tumors with low proliferation
Number of subjects: 152
Study 11395233 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy for tumors with high proliferation
Number of subjects: 152
Study 11395233 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (control group)
Number of subjects: 152
Study 9432453 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback-assisted pelvic floor muscle training
Number of subjects: 0
Study 9432453 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompted voiding program
Number of subjects: 0
Study 9432453 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment group
Number of subjects: 0
Study 9432453 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment group (control)
Number of subjects: 0
Study 9499549 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg medrogeston for six cycles
Number of subjects: 31
Study 9499549 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg dydrogesteron for six cycles
Number of subjects: 31
Study 2677376 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimazosin (50‐200 mg twice daily)
Number of subjects: 22
Study 2677376 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40‐160 mg twice daily)
Number of subjects: 22
Study 1108350 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulphamethoxazole, 2 tablets twice a day
Number of subjects: 30
Study 1108350 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin, 500 mg four times a day
Number of subjects: 30
Study 30862174 — intervention group
Group type: EXPERIMENTAL
Intervention: Active audiovisual stimulation (AVS)
Number of subjects: 16
Study 30862174 — intervention group
Group type: COMPARATOR
Intervention: Placebo-control audiovisual stimulation (AVS)
Number of subjects: 16
Study 29045745 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular advancement device (MAD)
Number of subjects: 30
Study 29045745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 26094857 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 receptor agonist exenatide
Number of subjects: 48
Study 26094857 — intervention group
Group type: COMPARATOR
Intervention: GLP-1 receptor blockade by exendin-9-39
Number of subjects: 48
Study 26094857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 23475594 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 386
Study 23475594 — intervention group
Group type: COMPARATOR
Intervention: Control groups
Number of subjects: 386
Study 22125984 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% Lignocaine with 1:100,000 epinephrine dental local anaesthetic
Number of subjects: 60
Study 22125984 — intervention group
Group type: COMPARATOR
Intervention: Control group (normotensive patients)
Number of subjects: 60
Study 19632976 — intervention group
Group type: EXPERIMENTAL
Intervention: Quit Smoking Network (QSN) treatment program
Number of subjects: 1028
Study 19632976 — intervention group
Group type: COMPARATOR
Intervention: Active Lives control condition
Number of subjects: 1028
Study 19632976 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-assigned treatments (various types)
Number of subjects: 1028
Study 16555159 — intervention group
Group type: EXPERIMENTAL
Intervention: RET proto-oncogene polymorphisms (exon2) in HD patients
Number of subjects: 94
Study 16555159 — intervention group
Group type: COMPARATOR
Intervention: RET proto-oncogene polymorphisms (exon2) in control subjects
Number of subjects: 94
Study 16555159 — intervention group
Group type: EXPERIMENTAL
Intervention: RET proto-oncogene polymorphisms (exon13) in HD patients
Number of subjects: 94
Study 16555159 — intervention group
Group type: COMPARATOR
Intervention: RET proto-oncogene polymorphisms (exon13) in control subjects
Number of subjects: 94
Study 16555159 — intervention group
Group type: EXPERIMENTAL
Intervention: RET proto-oncogene polymorphisms (exon11) in HD patients
Number of subjects: 94
Study 16555159 — intervention group
Group type: COMPARATOR
Intervention: RET proto-oncogene polymorphisms (exon11) in control subjects
Number of subjects: 94
Study 16555159 — intervention group
Group type: COMPARATOR
Intervention: RET proto-oncogene polymorphisms (exon15) in both HD patients and control subjects
Number of subjects: 94
Study 14964520 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational group intervention
Number of subjects: 58
Study 14964520 — intervention group
Group type: COMPARATOR
Intervention: Control group (nontreatment)
Number of subjects: 58
Study 11381720 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental decision-support materials to inform consumers about expected health plan costs
Number of subjects: 0
Study 11381720 — intervention group
Group type: COMPARATOR
Intervention: No supplemental decision-support materials
Number of subjects: 0
Study 9409050 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (200 mg tablets, two tablets administered pre-operatively)
Number of subjects: 127
Study 9409050 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two matching placebo tablets administered pre-operatively)
Number of subjects: 127
Study 8287650 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-hydroxy-L-tryptophan
Number of subjects: 9
Study 8287650 — intervention group
Group type: EXPERIMENTAL
Intervention: gamma-L-glutamyl-5-hydroxy-L-tryptophan
Number of subjects: 9
Study 8287650 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 3518771 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow release nifedipine 40 mg at 1 and 12 h
Number of subjects: 20
Study 3518771 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 100 mg at 0 h
Number of subjects: 20
Study 31648851 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinflunine/gemcitabine (VG)
Number of subjects: 62
Study 31648851 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin/gemcitabine (CG)
Number of subjects: 62
Study 29185089 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin (€4422)
Number of subjects: 0
Study 29185089 — intervention group
Group type: COMPARATOR
Intervention: Caspofungin (€2693)
Number of subjects: 0
Study 26682647 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone Call group
Number of subjects: 75
Study 26682647 — intervention group
Group type: COMPARATOR
Intervention: No Telephone Call group
Number of subjects: 75
Study 24687145 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic trabecular bypass (PTB)
Number of subjects: 42
Study 24687145 — intervention group
Group type: COMPARATOR
Intervention: Trabeculotomy (T)
Number of subjects: 42
Study 22324297 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope videolaryngoscope
Number of subjects: 60
Study 22324297 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 60
Study 20519807 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol administered just before a meal (50 mg)
Number of subjects: 0
Study 20519807 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol administered at 30 min after the start of a meal (50 mg)
Number of subjects: 0
Study 20519807 — intervention group
Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 0
Study 18535017 — intervention group
Group type: EXPERIMENTAL
Intervention: rs6983267 variant
Number of subjects: 2587
Study 18535017 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional haplotype containing rs10808555, rs6983267 and rs7837328
Number of subjects: 2587
Study 16435699 — intervention group
Group type: EXPERIMENTAL
Intervention: Spoken prompts
Number of subjects: 0
Study 16435699 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual prompts
Number of subjects: 0
Study 16435699 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficult tracking
Number of subjects: 0
Study 16435699 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracking performance
Number of subjects: 0
Study 12907008 — intervention group
Group type: EXPERIMENTAL
Intervention: PnCRM7 vaccine
Number of subjects: 8292
Study 12907008 — intervention group
Group type: COMPARATOR
Intervention: MnCC control vaccine
Number of subjects: 8292
Study 10566919 — intervention group
Group type: EXPERIMENTAL
Intervention: Ametop
Number of subjects: 32
Study 10566919 — intervention group
Group type: COMPARATOR
Intervention: EMLA
Number of subjects: 32
Study 8737229 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐HuEpo (200 U, subcutaneously administered, three times weekly for 4 weeks)
Number of subjects: 24
Study 8737229 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐HuEpo
Number of subjects: 24
Study 8737229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 1832972 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (CMI)
Number of subjects: 0
Study 1832972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7055169 — intervention group
Group type: EXPERIMENTAL
Intervention: Laminaria treatment (n = 45)
Number of subjects: 71
Study 7055169 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 26)
Number of subjects: 71
Study 30783732 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone (inhaled)
Number of subjects: 41
Study 30783732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 29885896 — intervention group
Group type: EXPERIMENTAL
Intervention: Short feeding duration with DCAD of -70 mEq/kg of DM (n = 29)
Number of subjects: 116
Study 29885896 — intervention group
Group type: EXPERIMENTAL
Intervention: Short feeding duration with DCAD of -180 mEq/kg of DM (n = 29)
Number of subjects: 116
Study 29885896 — intervention group
Group type: EXPERIMENTAL
Intervention: Long feeding duration with DCAD of -70 mEq/kg of DM (n = 28)
Number of subjects: 116
Study 29885896 — intervention group
Group type: EXPERIMENTAL
Intervention: Long feeding duration with DCAD of -180 mEq/kg of DM (n = 28)
Number of subjects: 116
Study 29885896 — intervention group
Group type: COMPARATOR
Intervention: DCAD -70 mEq/kg of DM
Number of subjects: 116
Study 29885896 — intervention group
Group type: EXPERIMENTAL
Intervention: DCAD -180 mEq/kg of DM
Number of subjects: 116
Study 29885896 — intervention group
Group type: COMPARATOR
Intervention: Short feeding duration (21 d)
Number of subjects: 116
Study 29885896 — intervention group
Group type: EXPERIMENTAL
Intervention: Long feeding duration (42 d)
Number of subjects: 116
Study 29885896 — intervention group
Group type: EXPERIMENTAL
Intervention: DCAD reduction from -70 to -180 mEq/kg of DM
Number of subjects: 116
Study 26707619 — intervention group
Group type: EXPERIMENTAL
Intervention: 50,000 IU/wk vitamin D3 (cholecalciferol)
Number of subjects: 183
Study 26707619 — intervention group
Group type: EXPERIMENTAL
Intervention: 5000 IU/d vitamin D3 (cholecalciferol)
Number of subjects: 183
Study 26707619 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 IU/d vitamin D3 (cholecalciferol)
Number of subjects: 183
Study 26707619 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese participants
Number of subjects: 183
Study 26707619 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanic participants
Number of subjects: 183
Study 24436294 — intervention group
Group type: EXPERIMENTAL
Intervention: Effective stimulation (ES) - skin pressure stimulation at the hallux tip and first metatarsal joint (0.58 ± 0.04 kg/mm(2))
Number of subjects: 16
Study 24436294 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (SS)
Number of subjects: 16
Study 22888833 — intervention group
Group type: EXPERIMENTAL
Intervention: Worksite aerobic exercise (60 min per week)
Number of subjects: 0
Study 22888833 — intervention group
Group type: COMPARATOR
Intervention: Reference group receiving lectures concerning healthy living
Number of subjects: 0
Study 18401648 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual-reality (VR) training environment for bimanual carrying (BC) task
Number of subjects: 8
Study 18401648 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual-reality (VR) training environment for needle passing (NP) task
Number of subjects: 8
Study 18401648 — intervention group
Group type: COMPARATOR
Intervention: Actual training environment for needle passing (NP) task
Number of subjects: 8
Study 17580534 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine once daily (n = 18)
Number of subjects: 48
Study 17580534 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin twice daily (n = 15)
Number of subjects: 48
Study 17580534 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin once daily at bedtime with more intensive self-monitoring (n = 15)
Number of subjects: 48
Study 15590586 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (50 mg on alternate days)
Number of subjects: 39876
Study 15590586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39876
Study 11576104 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide at 20% end‐expired
Number of subjects: 20
Study 11576104 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide at 40% end‐expired
Number of subjects: 20
Study 11576104 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide at 60% end‐expired
Number of subjects: 20
Study 11576104 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide (all concentrations)
Number of subjects: 20
Study 9672774 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg o.d. for 10 days)
Number of subjects: 28
Study 9672774 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 7720799 — intervention group
Group type: EXPERIMENTAL
Intervention: Heliosit
Number of subjects: 37
Study 7720799 — intervention group
Group type: COMPARATOR
Intervention: Concise
Number of subjects: 37
Study 2573918 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine
Number of subjects: 20
Study 2573918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1041620 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (simulation gaming)
Number of subjects: 60
Study 1041620 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 30783776 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen peptides (CP) 20 g day−1
Number of subjects: 24
Study 30783776 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (CON)
Number of subjects: 24
Study 29161454 — intervention group
Group type: EXPERIMENTAL
Intervention: Native-specific independent spiritual practices
Number of subjects: 134
Study 29161454 — intervention group
Group type: COMPARATOR
Intervention: Non-AI/AN participants
Number of subjects: 134